Disruptive distributors—new entrants in the provider acquisition game

In April our CEO, Christopher Kerns, kicked off our series on vertical integration with a post on the state of healthcare consolidation—what it looks like today, the promise and perils heralded by supporters and detractors, and a reality check. 

Kirsta Hackmeier
Kirsta Hackmeier
7 min read

At a glance

In April our CEO, Christopher Kerns, kicked off our series on vertical integration with a post on the state of healthcare consolidation—what it looks like today, the promise and perils heralded by supporters and detractors, and a reality check. A major focus of that piece—and of today’s consolidation landscape—is the accumulation of providers. We touched on the usual suspects: health plans, health systems, those hybrid payviders, and even tech companies. But a bit under the radar, drug distributors are also dipping their toes into the provider alignment pool. But while conducting research on the drug ecosystem, a surprising pattern caught our attention.

The silent giants

Drug distributors (the largest of which are also wholesalers) are intermediaries that sit smack dab in the middle of the pharmaceutical value chain. Unlike PBMs, who negotiate drug prices on behalf of insurers and purchasers, distributors actually purchase drugs directly from manufacturers. They then turn around and sell those medications to providers, hospitals, and pharmacies. Beyond acting as a clearinghouse for generic and brand name medications, distributors show up across the entire drug lifecycle, from R&D support and inventory management to shipping logistics and packaging disposal.

Let’s talk.

Questions? Want to learn more about what Union can do for you? We’d love to hear from you.